Tag

Nsclc

All articles tagged with #nsclc

health20 days ago•9 min saved

GLP-1 Drugs May Slow Metastasis in Obesity-Related Cancers, Early ASCO Data

Real-world TriNetX data presented at ASCO 2026 show GLP-1 receptor agonists used after cancer diagnosis linked to reduced metastatic progression across several obesity-related cancers, notably NSCLC, breast, colorectal, and hepatocellular carcinoma; in NSCLC, progression to stage IV was 10.0% with GLP-1 RAs vs 22.3% with DPP-4 inhibitors (HR 0.50). GLP-1 receptor expression also correlated with better overall survival, suggesting a potential class effect and the need for further study.

via The ASCO Post|

#breast-cancer #glp-1-receptor-agonists #health

business28 days ago•2 min saved

Pfizer's New NSCLC ADC Flops in Phase 3, but Combinations Could Revive the Program

Pfizer’s first new ADC after acquiring Seagen failed to meet its primary endpoint in a phase 3 nonsquamous NSCLC trial, showing no significant overall survival advantage vs docetaxel. The company cites a stronger signal in a patient subgroup with one prior therapy and notes ongoing phase 3 studies combining sigvotatug vedotin with pembrolizumab in first-line NSCLC, sustaining optimism for the program despite the setback.

via Fierce Biotech|

#business #nsclc #pembrolizumab

business1 month ago•12 min saved

GSK to buy Nuvalent for $10.6B, adding a multi-asset NSCLC portfolio

GSK will acquire Nuvalent for $10.6 billion in cash ($124 per share), gaining three NSCLC programs—zidesamtinib (ROS1) and neladalkib (ALK) as late-stage, potentially best-in-class therapies plus NVL-330 (HER2) and a preclinical portfolio—along with a platform for lung-cancer expansion. The deal, expected to close after regulatory approvals in 2026, is designed to be revenue- accretive from 2027 and-core EPS accretive by 2029 (including synergies and reprioritisation), financed largely by debt and cash with no expected rating impact and maintaining GSK’s dividend policy.

via GSK|

#alk #business #gsk

business1 month ago•58 min saved

Merck and Gilead Halt Phase 3 NSCLC Trial of Trodelvy with Keytruda After DMC Review

Merck and Gilead announced the discontinuation of the Phase 3 KEYNOTE-D46/EVOKE-03 trial evaluating Trodelvy in combination with Keytruda for previously untreated metastatic NSCLC with PD-L1 TPS ≥50% after the external Data Monitoring Committee reviewed the final PFS data and interim OS analysis. While progression-free survival improved numerically, it did not reach statistical significance, and the likelihood of a statistically significant overall survival result at the planned final analysis is low. Safety was consistent with the known profiles of both drugs. Regulators were informed, investigators and patients advised to discuss treatment with physicians, and there are no changes to ongoing Trodelvy or Merck studies. Data will be presented at a future medical meeting.

via Merck.com|

#business #gilead #keytruda

health1 month ago•7 min saved

Ivonescimab+chemo extends survival in first-line squamous NSCLC at ASCO

Akeso’s ivonescimab, a PD-1xVEGF bispecific, plus chemotherapy significantly extended overall survival in first-line, untreated squamous NSCLC in the Harmoni-6 trial, cutting death risk by 34% with a median OS of 27.9 months vs 23.7 months (p=0.0017) versus Tevimbra-chemo. The interim China-only ASCO presentation showed benefit across PD-L1–negative and –positive patients, but experts caution the follow-up is immature and point to safety signals and trial eligibility criteria that may limit global applicability, signaling a need for further studies.

via Fierce Pharma|

#harmoni-6 #health #ivonescimab

business3 months ago•6 min saved

Merck's PD-1xVEGF bispecific MK-2010 shows early NSCLC signals in China trial

Merck reported first clinical data from its PD-1xVEGF bispecific MK-2010 in a Chinese phase 1/2 NSCLC trial, showing unconfirmed ORRs of 55% in treatment-naïve PD-L1-positive patients at 20 mg/kg every three weeks and 44% at 30 mg/kg, with lower responses in previously treated patients. Across backfill cohorts (n=72) the safety profile included dose-limiting toxicities like grade 3 proteinuria and hemoptysis, several bleeding events, and deaths in higher-dose arms, though the maximum tolerated dose has not been reached. Results are early, from small cohorts, and Merck has not disclosed phase 3 plans, as rivals advance multiple PD-(L)1xVEGF programs; more data are needed to define MK-2010's potential role.

via Fierce Biotech|

#business #clinical-trial #immunotherapy

health4 months ago•2 min saved

FDA Grants Second National Priority Voucher-Driven Approval for Hernexeos in HER2-Mutant NSCLC

The FDA approved Hernexeos (zongertinib) for adults with unresectable or metastatic non-squamous NSCLC harboring activating HER2 (ERBB2) mutations, extending accelerated approval to first-line patients under the Commissioner's National Priority Voucher (CNPV) pilot program. The decision followed strong data showing 76% of untreated patients had substantial tumor shrinkage, higher than typical 30-45% responses, and came 44 days after filing on Jan 13, 2026. The move underscores fast-tracked review through the CNPV program, which also provides voucher-related benefits; the agency noted Breakthrough Therapy and Priority Review designations and highlighted safety risks such as hepatotoxicity and other common side effects.

via fda.gov|

#health #her2 #hernexeos

business4 months ago•19 min saved

ImmunityBio’s ANKTIVA Delivers 700% Revenue Jump, Expands to 33 Countries and Secures First Lung Cancer Approval

ImmunityBio reports 2025 ANKTIVA net product revenue of about $113 million (up ~700% YoY) with 750% unit growth, expanding approvals to 33 countries across four jurisdictions and securing Saudi Arabia’s first lung-cancer approval, while strengthening European and Middle East partnerships and outlining a 3-year plan to use ANKTIVA as the Cancer BioShield backbone across multiple trials.

via ImmunityBio|

#anktiva #business #immunitybio

health5 months ago•7 min saved

Sunrise advantage: morning immunotherapy linked to longer survival in lung cancer

A randomized study in 210 patients with non-small-cell lung cancer found that receiving the first immunotherapy dose before 3 p.m. significantly improved outcomes compared with later dosing: about 11.3 months progression-free survival versus 5.7 months and roughly 45% alive versus 15% at follow-up, with morning treatment also showing more cancer-killing T cells. Experts caution that replication is needed, though a confirmatory trial is underway; the work was published in Nature Medicine.

via cnn.com|

#cancer #circadian-rhythm #health

healthcare1 year ago•3 min saved

Summit's Lung Cancer Drugs Show Mixed Results in Global Trials

Akeso and Summit Therapeutics' drug ivonescimab showed promising results in delaying progression of certain lung cancers in a global phase 3 trial, with significant improvements in progression-free survival, though overall survival benefits are still being evaluated. The drug demonstrated consistent effects across Asian and Western populations, and the companies plan to seek FDA approval, despite some investor disappointment over the overall survival data.

via Fierce Pharma|

#healthcare #ivonescimab #lung-cancer

healthcare1 year ago•2 min saved

Daiichi and Merck Withdraw Lung Cancer Drug Filing After Survival Data Miss

Merck and Daiichi Sankyo have voluntarily withdrawn their BLA for HER3-DXd, a drug for NSCLC, after phase 3 trial results failed to meet survival endpoints and discussions with the FDA. Despite previous promising data, the drug's development faces setbacks, but the companies remain committed to ongoing research across multiple cancer types.

via Fierce Biotech|

#daiichi-sankyo #fda-withdrawal #healthcare

medical-oncology2 years ago•4 min saved

"ESMO Abstract Leak Unveils Exciting NSCLC Therapies and Neoadjuvant Nivolumab Advancements"

The European Society for Medical Oncology (ESMO) Congress 2023 has experienced an embargo breach, revealing promising therapies for non-small cell lung cancer (NSCLC). Bristol Myers Squibb's Opdivo demonstrated positive results in two Phase III studies, showing a reduction in disease recurrence and improved survival rates. Mirati's adagrasib, when combined with Keytruda, showed strong first-line promise in NSCLC patients. BeiGene's tislelizumab, in combination with chemotherapy, achieved a major pathological response in a Phase III trial. Johnson & Johnson's Rybrevant-lazertinib combination demonstrated potential as a new standard of care for EGFR-mutated NSCLC. These findings will be presented at the ESMO Congress in October.

via BioSpace|

#adagrasib #esmo #medical-oncology